VCP Proteostasis Modulation Therapy for ALS/FTD

Overview

VCP Proteostasis Modulation is a novel therapeutic strategy targeting the [Valosin Containing Protein (VCP](/proteins/vcp-p97)/p97), a genetically validated AAA+ ATPase that is mutated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and inclusion body myopathy. VCP is essential for protein quality control, ER-associated degradation ([ERAD](/mechanisms/proteostasis-erad-pathway)), autophagosome maturation, and DNA repair — all pathways critically impaired in neurodegenerative disease.

Therapeutic Rationale

Genetic Evidence

[VCP](/proteins/vcp-p97) mutations cause a spectrum of neurodegenerative disorders[@johnson2010][@wong2020]:

• IBMPFD (Inclusion Body Myopathy with Paget disease and Frontotemporal Dementia) — autosomal dominant
• ALS — [VCP](/proteins/vcp-p97) mutations account for ~1-2% of familial ALS cases
• FTD — [VCP](/proteins/vcp-p97) mutations found in familial FTD cases
• PD — VCP variants associated with Parkinson's disease risk

The strong genetic evidence linking VCP to neurodegeneration makes it a compelling therapeutic target.

Mechanism

VCP functions as a molecular segregase that uses ATP hydrolysis to extract ubiquitinated substrates from membranes, protein complexes, and chromatin[@meyer2012][@watts2004]:

...

Overview

VCP Proteostasis Modulation is a novel therapeutic strategy targeting the [Valosin Containing Protein (VCP](/proteins/vcp-p97)/p97), a genetically validated AAA+ ATPase that is mutated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and inclusion body myopathy. VCP is essential for protein quality control, ER-associated degradation ([ERAD](/mechanisms/proteostasis-erad-pathway)), autophagosome maturation, and DNA repair — all pathways critically impaired in neurodegenerative disease.

Therapeutic Rationale

Genetic Evidence

[VCP](/proteins/vcp-p97) mutations cause a spectrum of neurodegenerative disorders[@johnson2010][@wong2020]:

• IBMPFD (Inclusion Body Myopathy with Paget disease and Frontotemporal Dementia) — autosomal dominant
• ALS — [VCP](/proteins/vcp-p97) mutations account for ~1-2% of familial ALS cases
• FTD — [VCP](/proteins/vcp-p97) mutations found in familial FTD cases
• PD — VCP variants associated with Parkinson's disease risk

The strong genetic evidence linking VCP to neurodegeneration makes it a compelling therapeutic target.

Mechanism

VCP functions as a molecular segregase that uses ATP hydrolysis to extract ubiquitinated substrates from membranes, protein complexes, and chromatin[@meyer2012][@watts2004]:

[ERAD](/mechanisms/proteostasis-erad-pathway): VCP extracts misfolded proteins from the ER for proteasomal degradation[@buchan2013]

Autophagy: VCP is required for autophagosome maturation and lysosomal fusion[@nalbandian2012]

Protein Quality Control: VCP disaggregates and extracts damaged proteins

DNA Repair: VCP facilitates DNA double-strand break repair

In ALS/FTD with [VCP](/proteins/vcp-p97) mutations:

• Impaired [ERAD](/mechanisms/proteostasis-erad-pathway) leads to [ER stress](/mechanisms/er-stress-neurodegeneration) and [UPR](/entities/unfolded-protein-response) activation
• Defective [autophagy](/entities/autophagy) causes accumulation of [protein aggregates](/mechanisms/protein-aggregation)
• [TDP-43](/proteins/tardbp-protein) mislocalization is exacerbated by VCP dysfunction
• Mitochondrial quality control is compromised

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | First-in-class mechanism targeting genetically validated VCP |
| Mechanistic Rationale | 9 | Strong genetic evidence + multiple preclinical studies on [proteostasis](/mechanisms/proteostasis-network) |
| Addresses Root Cause | 9 | Targets core [proteostasis](/mechanisms/proteostasis-network) dysfunction in ALS/FTD |
| Delivery Feasibility | 6 | Small molecule feasible; [BBB](/entities/blood-brain-barrier) penetration optimization needed |
| Safety Plausibility | 6 | Modulation preferred over complete inhibition; toxicity risk |
| Combinability | 8 | Synergizes with [autophagy](/entities/autophagy) enhancers, [proteasome modulators](/therapeutics/proteasome-inhibitors) |
| Biomarker Availability | 7 | p75 ECD, CSF NfL, aggregate burden imaging |
| De-risking Path | 7 | iPSC [neurons](/entities/neurons) from VCP mutation carriers available |
| Multi-disease Potential | 8 | ALS, FTD, IBM, and PD share VCP-related [proteostasis](/mechanisms/proteostasis-network) defects |
| Patient Impact | 8 | Addresses fundamental mechanism in genetically predisposed |
| Total | 76/100 | |

Category

Novel Target — VCP is a genetically validated target with no current therapeutic programs specifically targeting this mechanism in neurodegeneration.

Disease Coverage

| Disease | Relevance |
|---------|-----------|
| Amyotrophic Lateral Sclerosis | Primary — [VCP](/proteins/vcp-p97) mutations cause familial ALS |
| Frontotemporal Dementia | Primary — [VCP](/proteins/vcp-p97) mutations cause FTD |
| Inclusion Body Myopathy | Primary — hallmark of VCP disease |
| [Parkinson's Disease](/diseases/parkinsons-disease-dementia) | Secondary — VCP variants are risk factors |
| [Alzheimer's Disease](/diseases/alzheimers-disease) | Low — not a primary genetic risk |

Development Strategy

Target Validation

Genetic Confirmation: Confirm VCP mutation carrier status

Biomarker Assessment: Baseline p75 ECD (ectodomain), CSF NfL, [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain

iPSC Models: Generate motor neurons from VCP mutation carriers for in vitro testing

Aggregate Assessment: Measure [TDP-43](/proteins/tardbp-protein), p62, and ubiquitin burden

Therapeutic Approach

Small Molecule VCP Modulators:

• Screen for compounds that enhance VCP ATPase activity in the presence of pathogenic mutations
• Focus on [proteostasis](/mechanisms/proteostasis-network) restoration without overactivation
• Optimize for CNS penetration and engagement

Alternative Approaches:

• Gene Therapy: AAV-mediated wild-type VCP expression
• Protein Homeostasis Enhancers: Broader [proteostasis](/mechanisms/proteostasis-network) modulators that work through VCP
• Autophagy Inducers: Compensate for VCP-dependent autophagic defects

Combination Potential

VCP modulation could be combined with:

• Autophagy enhancers — compensate for impaired autophagosome maturation
• Proteasome modulators — enhance [ERAD](/mechanisms/proteostasis-erad-pathway) function
• [TDP-43](/proteins/tardbp-protein) targeting — address downstream aggregation
• Neuroprotective agents — broad support for neuronal survival

Actionable Next Steps

Lab Experiments

VCP ATPase Assay: Develop biochemical assay using fluorescent ATP detection

Compound Screening: Screen 10,000+ compound library for VCP modulators

iPSC Neuron Testing: Measure [TDP-43](/proteins/tardbp-protein) mislocalization, [autophagy](/entities/autophagy) flux, [ER stress](/mechanisms/er-stress-neurodegeneration) in treated cells

Hit-to-Lead Optimization: SAR studies for lead compounds

In Vivo Validation: Test lead compounds in VCP mouse models

Clinical Protocol Design

Patient Population: Early-stage ALS/FTD patients with confirmed [VCP](/proteins/vcp-p97) mutations

Enrollment Strategy: Partner with ALS clinics, the ALS Association, and genetic testing programs

Enrichment: Use p75 ECD as a target engagement biomarker

Endpoints: ALSFRS-R, FTD rating scale, NfL, survival

Company Partnership Opportunities

Biogen — Established ALS pipeline and genetics program

Denali Therapeutics — Proteostasis and lysosomal pathway expertise

Ionasis Pharmaceuticals — CNS-focused small molecule development

Rarebase — Precision therapy for genetic neurological diseases

Implementation Roadmap

Phase 1: Target Validation & Lead Identification (Months 1-18)

| Milestone | Timeline | Cost |
|-----------|----------|------|
| iPSC motor neuron generation from VCP carriers | Months 1-4 | $400K |
| VCP ATPase assay development | Months 2-6 | $300K |
| Compound library screening | Months 5-10 | $600K |
| Lead optimization and in vitro PK | Months 8-18 | $1.2M |
| Phase 1 Total | | $2.5M |

Phase 2: Preclinical Development (Months 16-32)

| Milestone | Timeline | Cost |
|-----------|----------|------|
| GLP toxicology | Months 16-24 | $2.0M |
| IND-enabling studies | Months 20-28 | $1.5M |
| Clinical trial design | Months 24-32 | $500K |
| Phase 2 Total | | $4.0M |

Phase 3: Clinical Development (Months 30-60)

| Milestone | Timeline | Cost |
|-----------|----------|------|
| Phase 1 first-in-human | Months 30-40 | $3.5M |
| Phase 2 efficacy signal | Months 38-52 | $10M |
| Phase 3 registration trial | Months 50-60 | $25M |
| Phase 3 Total | | $38.5M |

Total Program Cost: $45M over 60 months

Risks and Mitigation

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Target engagement insufficient | Medium | High | Multiple readouts; iterative optimization |
| Off-target toxicity | Medium | High | Early safety pharmacology |
| Lack of efficacy signal | Medium | High | Genetic enrichment strategy |
| BBB penetration | Medium | Medium | Partner with BBB delivery experts |

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Cross-Links

Diseases

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia)
• [Inclusion Body Myopathy](/diseases/inclusion-body-myopathy)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

Mechanisms

• [Proteostasis](/mechanisms/proteostasis-network)
• [ERAD Pathway](/mechanisms/proteostasis-erad-pathway)
• [Autophagy](/mechanisms/autophagy)
• [Protein Quality Control](/mechanisms/protein-quality-control-network)
• [DNA Repair](/mechanisms/dna-repair-pathways)

Proteins

• [VCP/p97](/proteins/vcp-p97)
• [UBQLN2](/genes/ubqln2)
• [TDP-43](/proteins/tardbp)
• [C9orf72](/genes/c9orf72)
• [OPTN](/proteins/optn)

Cell Types

• [Motor Neurons](/cell-types/motor-neurons)
• [Neurons](/cell-types/neurons)
• [Astrocytes](/cell-types/astrocytes)

Treatments

• [DBeQ](/therapeutics/dbeq)
• [CB-5083](/therapeutics/cb-5083)
• [ATPase Inhibitors](/therapeutics/atpase-inhibitors)

References

[Johnson JO, Mandrioli J, Benatar M, et al, Exome sequencing reveals VCP mutations as a cause of familial ALS (2010)](https://pubmed.ncbi.nlm.nih.gov/21167468/)

PMID: 33106593(https://pubmed.ncbi.nlm.nih.gov/33106593/)

[Meyer H, Bug M, Bremer S, Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system (2012)](https://pubmed.ncbi.nlm.nih.gov/22645131/)

[Watts GD, Wymer J, Kovach MJ, et al, Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant VCP (2004)](https://pubmed.ncbi.nlm.nih.gov/15502839/)

[Buchan JR, Kolaitis RM, Taylor JP, et al, Eukaryotic stress granules are dynamically regulated by VCP (2013)](https://pubmed.ncbi.nlm.nih.gov/23835579/)

[Nalbandian A, Llewellyn KJ, Kitazawa M, et al, The homozygote VCP(R155H/R155H) mouse model exhibits systemic autophagy deficiency and motor neuron degeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22797921/)

Pathway Diagram

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [VCP-Mediated Autophagy Enhancement](/hypothesis/h-18a0fcc6) — <span style="color:#ffd54f;font-weight:600">0.54</span> · Target: VCP

Pathway Diagram

The following diagram shows the key molecular relationships involving VCP Proteostasis Modulation Therapy for ALS/FTD discovered through SciDEX knowledge graph analysis: